Neuren Pharmaceuticals (ASX:NEU) PEG Ratio: N/A (As of Jul. 02, 2026)


ASX:NEU Neuren Pharmaceuticals Ltd ASX:NEU
54 GF Score
Price A$17.00
GF Value A$6.79
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Neuren Pharmaceuticals PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Neuren Pharmaceuticals's PE Ratio without NRI is 72.96. Neuren Pharmaceuticals's 5-Year EBITDA growth rate is 0.00%. Therefore, Neuren Pharmaceuticals's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Neuren Pharmaceuticals's PEG Ratio or its related term are showing as below:



ASX:NEU's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.03
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Neuren Pharmaceuticals  (ASX:NEU) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Neuren Pharmaceuticals PEG Ratio Related Terms


Neuren Pharmaceuticals PEG Ratio Historical Data

* Premium members only.

The historical data trend for Neuren Pharmaceuticals's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuren Pharmaceuticals PEG Ratio Chart

Neuren Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Neuren Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:NEU vs VRTX, REGN, ALNY: PEG Ratio Comparison

For the Biotechnology subindustry, Neuren Pharmaceuticals's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuren Pharmaceuticals PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuren Pharmaceuticals's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Neuren Pharmaceuticals's PEG Ratio falls into.


ASX:NEU
54GF Score
Neuren Pharmaceuticals Ltd ASX:NEU
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuren Pharmaceuticals PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Neuren Pharmaceuticals's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=72.961373390558/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Neuren Pharmaceuticals (ASX:NEU) Overvalued in 2026?

Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued. The current stock price of A$17.00 is trading 150.4% above its estimated GF Value™ of A$6.79. GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ASX:NEU:

  • PEG Ratio: N/A
  • GF Value™: A$6.79 vs. price of A$17.00 (150.4% above fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the ASX:NEU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neuren Pharmaceuticals Business Description

Other Exchanges NURPF:USANK9:Germany
Address 117 Camberwell Road, Suite 1.01, Hawthorn East, Melbourne, VIC, AUS, 3123
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
54GF Score

Get the complete analysis for ASX:NEU

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$17.00
Price
A$6.79
GF Value